Japan: The Patentability of Medicinal Inventions Related to Personalised Medicine in Japan

Last Updated: 16 March 2006

By Itsuki Shimbo, Research Priority Committee Riken, Andrew Cobden, Lovells Tokyo Office and Koichi Sumikura, National Graduate Institute for Policy Studies (GRIPS)


As the difficulties in producing new chemical entities continue for pharmaceutical companies, their research strategies have recently emphasised not only the development of new medicines, but also life cycle management. This process is designed to forestall the emergence of generic medicines by protecting related inventions, such as those that expand the range of applicable diseases or optimise methods of administering a medicine, after the expiration of the original basic patent. An example of expanding the range of applicable diseases is the immunosuppressant FK506, which was originally used for organ transplantation and was later developed for use in an atopic dermatitis medicine. Patents have already been granted for a "medicinal invention intended to specify by the mode of medical treatment" (see Table 1, Claim 2), which is designed to increase the medicinal effect, or to reduce side effects. An example of a patent for a combination of known medicinal ingredients is a patent for a combination therapy for hepatitis C using interferon a and ribavirin1. Research is being done on methods of administration matched to the patient’s genetic polymorphism of the patient’s condition based on biological information obtained through biochemical diagnosis – thereby increasing the promise of personalised medicine.

Many pharmaceutical companies contend that uses of medicine, as well as the medicines themselves, should be covered by patent protection. However, patents for methods of using medicines come under "inventions relating to medical treatment methods", which are not considered patentable in Japan. The Japanese Government Intellectual Property Policy Headquarters has been considering this issue and various parties have given their opinions regarding inventions related to medical activity2. Following this work, in April 2005, the Japan Patent Office ("JPO") clarified its Examination Guidelines for "inventions related to the use of medicines"3.


In Japan, patentable inventions are stipulated as being "industrially applicable inventions",4 whereas inventions relating to surgery or therapy and diagnostic methods practised on the human body – so-called inventions for medical treatment methods – are not patentable because they are not considered to be industrially applicable. Therefore, a claim in the form "Use of substance or composition X for the treatment of disease Y…" will be regarded as relating to an invention for medical treatment methods, and excluded from patentability. A similar provision is provided in Article 52(4) of the European Patent Convention (EPC).5

Table 1

Examples of claims involving a combination of medicines or the optimisation of dosing interval and given dose

Claim 1 (Reference case 1)
Dosage form claim

A tablet medicine of immunopotentiating agent containing 550-650 mg of a compound Z or its pharmacologically admissive salts per tablet.

Claim 2 (Kit claim)

A drug preparation containing Taxol for treatment of patients suffering from cancer who pose concerns of haematological toxicity accompanying treatment with Taxol, said drug preparation being packaged for parenteral administration such that between about 135 mg/m2 and about 175 mg/m2 of Taxol is administered over a period of approximately three hours. (JP 2848760, US 5621001).

Claim 3 (Case 1)

Claim 3 (Case 1) Combination An anticancer drug formulated by combining a compound A with a compound B.

Claim 4 (Case 1) Combination

The anticancer drug according to Claim 1, wherein the compound A is dosed through an administrating path selected from a group consisting of a vein path and a subcutaneous path, and the compound B is orally dosed, respectively with doses of 10-50 mg/kg and 1-30 mg/kg daily or three times in a week.

Claim 5 (Case 8)
Different target patients

A hepatitis C treatment drug containing compound A for treating with an a genotype, characterised in that it is administered initially at a quantity of 5.0 mg/kg, and subsequently at a quantity of 0.3 mg/kg to 0.5 mg/kg per dose every other day.

Claim 6 Swiss-type claim

Use of alendronic acids or pharmaceutically acceptable salt thereof, or a mixture thereof, for the manufacture of a medicament for inhibiting bone resorption in a human wherein said medicament is adapted for oral administration, in a unit dosage which comprises from about 8.75-140 mg alendronic acid or a pharmaceutically acceptable salt thereof, on an alendronic acids active weight basis, according to a continuous schedule having a periodicity from about once every 3 days to about once every 16 days. (EP 0998292B1).

Source: Table 1 is cited in modified form from the Japan Patent Office Examination Guidelines. Case numbers in the tables are those in the Examination Guidelines

However, "an invention of a product" (a product invention) such as a pharmaceutical or medical device, even though its objective is for medical treatment, still meets the requirement of industrial applicability. In the EPC, the same general concept is made clear in the current provisions of Article 52(4) EPC.

In Japan, a patent for a medicinal invention can be obtained directly as "an invention of a product". Patents for medicinal inventions can be granted when a specific medicinal use of a known compound is discovered. It is not an invention of the substance itself but rather the substance and its particular medical use which is the invention. In other words, a medicinal invention is understood to be "a product invention" based on finding a property of a specific pharmacological function in one compound or one group of compounds, and finding a new medicinal use of applying the property to a new specific disease.

In the United States’ patent systems, unlike the Japanese and European, if an invention is for a known product but limited to a novel medical use, because the product itself is the same, it will not have novelty as a product invention and will be deemed unpatentable.6 However, inventions for medical treatment methods can be patented just like inventions in any other technical field. Therefore, if a medicinal use is discovered for a known chemical substance X, a patent can be obtained by claiming "Use of chemical substance X for the treatment of disease Y".

Novelty of medicinal use inventions

Novelty of medicinal inventions can be judged by classifying the inventions into one of the following categories:

  • first medicinal use, where a medicinal use for either a novel or a known chemical substance is discovered for the first time and
  • second medicinal use invention, where another new medicinal use is discovered for a publicly known medicine.

In Japan, for a first medicinal use invention, if somebody is first to discover the use of chemical substance X as a medicine, and if that chemical substance is a novel substance, that person can obtain two patents - one for chemical substance X itself, and the other for a medicine containing chemical substance X. On the other hand, in the case of a known chemical substance, only a medicine containing chemical substance X may be patented. As for a second medicinal use invention, a claim will be in the form "A medicine for disease Z comprising a medical ingredient Y", which is more limited than for a first medicinal use invention.

Novelty is therefore judged from two viewpoints: the compound per se and the medicinal use of such compound applied to a specific disease based on a particular property. A characteristic of the JPO approach is that novelty will be evaluated without distinguishing between first medicinal use inventions and second medicinal use inventions. A characteristic of the Japanese patent system is that a product invention limited by use – not just in cases of medicinal inventions – can have novelty because an association with a newly discovered use will be considered as a part of the invention, even where the medical ingredient is known.

Under Article 54(5) of the EPC, a claimed first medical use invention involving a known product can have novelty as a product invention based on an express exception regarding novelty, whereas for a claimed second medical use invention, this exception does not apply. In principle, an invention related to a novel use of a known product may be patentable using a claim directed to that specific use. A difficulty arises, however, in respect of medical use inventions because of Article 52(4). This problem has been overcome to allow patents for second medical use inventions with a Swiss-type claim: "use of (known) substance X for the manufacture of a medicament for therapeutic application Y"7. The need for Swiss-type claims for second medical use inventions should be removed as Article 54(5) of the EPC was amended in November 2000 (ref.88). After implementation of the amended article, it is expected that the EPC approach will be the same as that in Japan.

Furthermore, first medicinal use inventions have a greater significance for a patent strategy compared to second medicinal use inventions. This is because, so long as the substance is recognised to be effective against a single disease, even if it may not be effective against many other diseases, the JPO will allow a broad claim to a medicine containing that substance, not limited to treating a specific disease. In the European Patent Office (EPO) as well, a first medicinal use invention can generally obtain a patent for the medicine itself, which is in the form "X for use in therapy"9. Although allowed by the EPO, there is some doubt as to the validity of such wide claims in the UK, if the claim extends beyond the technical contribution made by the inventor.10


Sometimes, the combination of several medicinal ingredients may be discovered to have a synergistic effect or a remarkable efficacy that could not be obtained with the individual medicinal ingredients, or it may be discovered that changing the mode of medical treatment, such as the dosing interval and given dose, from the prior art enhances the prior art effects or reduces harmful side effects. It would be more natural to claim these kinds of inventions as "an invention of a method," but method claims will not be allowable because they will be regarded as medical treatment methods. Therefore, in practice, these inventions have been claimed as product inventions. A patent with the objective of optimising the frequency of administration and dosage of Taxol is an example of this (see Table 1, Claim 2). However, it is difficult to distinguish methods, such as combining medicines or optimising dosing intervals and given dose, from prescription and medicine administration activities of physicians. Thus the Intellectual Property Policy Headquarters has explicitly indicated that there should be patent protection "for the manufacture and sale of medicines" so as not to include the activities of a physician, and has proposed that these should be protected as "an invention of a product." Accordingly, the JPO has clarified in its amended examination guidelines that "medicinal inventions intended to specify the mode of medical treatment such as the frequency of administration and dosage" and "combinations of medicinal ingredients" are to be patented as product inventions. Table 1 shows some claims for these inventions: combination of medical ingredients (Claims 3 and 4) and optimisation of dosing interval(s) and given dose(s) (Claims 1, 2 and 5).

The EPO allows patents containing Swiss type claims for inventions that specify the frequency of administration and dosage of a medicine or the method of use of a medicine (Claim 6). More recently, claims have been allowed when the sole feature of novelty was the mode of drug administration (subcutaneous injection instead of the known intramuscular injection)11 and also where novelty resided only in the frequency of administration (nifedipine crystals for oral treatment of hypertension, to be administered once or twice daily).12 However, in the UK, a patent for a medicinal invention specifying the frequency of administration and dosage was invalidated on grounds that it was in reality a method of treatment and would substantially monopolise the activity of physicians.13

The approach used in Japan for determining the novelty of claimed inventions concerning combination or optimisation is as follows: according to the amended examination guidelines, when the mode of medical treatment such as dosing interval and given dose is indicated, novelty of the invention is determined differently depending on whether the mode of treatment is reflected in a dosage form or a spatially separated and packaged kit (Claims 1 and 2), or not (Claim 5). As explained above, novelty of a medicinal invention is judged from two viewpoints: the compound per se and the medicinal use. Therefore, when the mode of treatment is reflected in a dosage form or a kit, if the specified ingredient constitution in the dosage or the kit is novel, even though it is a known medicine, the compound itself is considered novel. On the other hand, when the mode is not reflected in a dosage form or a kit, if the compound is a known medicine, even though they have the novel mode of medical treatment, the novelty of the compound is denied.

Thus, the novelty of the medicinal use, such as specifying target patients, is required for the invention to have novelty (Claim 5).

However, we consider that novelty should not be judged differently, depending on whether or not the mode of treatment is reflected in a dosage form or kit. The description of modes of treatment, such as dosing interval and given dose, given in claims can be information on administration written on the package of a medicine or an instruction document in general. This document brings the medicine used in the mode of treatment within the claim. For this reason, we suggest that the description of the mode of treatment can be a constituent feature of an invention. Moreover, as a compound can perform the required medicinal effect only when it is used with the specific dosing interval and given dose, we consider that the compound itself is just an element of the invention. Taken together, if the mode of treatment is novel, the invention should be regarded as novel. Otherwise, for cases where the mode of treatment is optimised for a combination of publicly known medicinal ingredients, only claims for a dosage form or a kit will be available, which seems to result in too narrow a scope of rights to obtain adequate protection.


Personalised medicine achieves a finely tuned treatment by differentiating the patients to whom medicines will be administered based on each patient’s genetic expression status and gene polymorphism or on some biochemical diagnosis. The Examination Guidelines have made it clear that a medicinal use invention where the target patients are different from those of the known medicines can be protected. In cases where side effect information on a medicine is obtained by analysis of genetic polymorphism, there is also the possibility of being able to obtain a patent for a medicinal invention by specifying the class of patients, so as to exclude those adversely affected. Furthermore, the new guidelines have also made it clear that combinations of medicines and optimisation of dosage and frequency of administration will be protected as "an invention of a product". We consider that the new guidelines, by giving enhanced patent protection to these inventions, will have a great impact on pharmaceutical companies and have an effect on their research strategies.


We thank Toshio Miyake of Kato Patent Firm for advice on this article. First published in Nature.


1 Patent Nos. JP H10-506640 and US 6299872.

2 Intellectual Property Policy Headquarters. "Regarding the state of patent protection for methods related to medical activity." November 22, 2004.

3 Japan Patent Office. Examination guidelines for patent and utility model in Japan, Part VII: Examination guidelines for specific technical field, "Medicinal Inventions." 15 April 2005.

4 Japan Patent Law, Article 29, Subsection 1.

5 Article 52 of the EPC was amended on 29 November 2000. When the amended provisions are implemented, the methods of treatment currently in Article 52(4) EPC will become an exception to patentability under Article 53 EPC, rather than being regarded as not susceptible to industrial application under the present Article 52 EPC.

6 In re Schoenwald, 946 F.2d 1122 (Fed. Cir. 1992).

7 G5/83-EISIA/Second Medical Use [1985] O.J. EPO, 64.

8 Under the new Article 54(5) EPC, patentability will not be excluded on the ground of lack of novelty for any substance or composition, comprised in the state of the art, for any specific use in a method referred to in the present Article 52(4), provided that such use is not comprised in the state of the art.

9 T128/82 Hoffmann-La Roche/pyrrolidine-derivatives [1984] O.J. EPO, 164.

10 UK Patent Office. F. Hoffmann-La Roche AG BL 01/192/04 7 July 2004.

11 T51/93 Serono.

12 T570/92 Bayer (see also T56/97 Takeda).

13 Bristol-Myers Squibb Company v Baker Norton Pharmaceutical Inc [2001] RPC 1.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions